ReviewJournal of clinical medicine2024

IBD Patients with Primary or Secondary Nonresponse to Ustekinumab Benefit from Dose Escalation or Reinduction.

Filippo Vernia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.